Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 8Recurrence 7Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Lymphoma 4Dendritic Cell Sarcoma, Interdigitating 2Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Cytokine Release Syndrome 1Aggression 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × glofitamab × Clear all
NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡